Mektovi (binimetinib) — CareFirst (Caremark)
Central nervous system cancers (glioma, meningioma, astrocytoma)
Initial criteria
- BRAF V600 mutation-positive (e.g., BRAF V600E or V600K) gliomas, meningiomas, or astrocytomas
Reauthorization criteria
- Continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months